India's immunotherapy crisis: Life-saving cancer drugs priced beyond reach
A new study has highlighted the extreme cost of immunotherapy drugs in India, placing life-saving treatments out of reach for most patients. Drugs like Pembrolizumab and Nivolumab, used for cancers including head and neck tumours, come with price tags that dwarf average incomes. Researchers warn that these costs risk pushing families into financial ruin while treating just a fraction of the patients in need.
Head and neck cancers are widespread in India, often tied to tobacco, areca nut, and alcohol use. Many patients receive diagnoses only at advanced stages, forcing them to fund treatment from personal savings. Pembrolizumab, a key immunotherapy drug, costs nearly 80 times the average monthly income for a six-month course. Another drug, Nivolumab, exceeds 20 times the same benchmark.
The financial burden is stark. The amount spent on one Pembrolizumab patient could instead treat 18 to 22 patients using cheaper targeted therapies. Lead author Dr. Arjun Singh points to drug pricing that ignores real-world earnings, leaving most families unable to afford care. Senior author Dr. Pankaj Chaturvedi stresses that high costs not only limit access but also drive families into poverty.
The problem extends beyond India. While the study's full scope remains unclear, developed nations also face challenges in balancing immunotherapy benefits with affordability. Yet in India, where incomes are lower, the gap between cost and accessibility is far wider.
Immunotherapy offers proven survival benefits but remains financially unsustainable for many. In India, the cost disparity forces difficult choices between effective treatment and financial stability. Without more affordable options, patients and families will continue to bear the weight of these unaffordable therapies.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Sleep Maxxing Trends and Tips: New Zealanders Seek Better Rest
- Over 1.7M in Baden-Württemberg at Poverty Risk, Emmendingen's Housing Crisis Urgent
- Life Expectancy Soars, But Youth Suicide and Substance Abuse Pose Concern
